## **Core Concept**
Malignant hyperthermia (MH) is a rare but life-threatening medical emergency that can arise during general anesthesia with certain volatile anesthetic agents and depolarizing muscle relaxants. It is characterized by a hypermetabolic state, muscle rigidity, and elevated body temperature. The condition is genetically predisposed and associated with mutations in the **ryanodine receptor type 1 (RyR1)** gene.

## **Why the Correct Answer is Right**
The correct answer, , is a known trigger for malignant hyperthermia. It is a volatile anesthetic agent that can induce MH in susceptible individuals by causing an abnormal release of calcium from the sarcoplasmic reticulum, leading to sustained muscle contraction and hypermetabolism. The RyR1 receptor plays a critical role in this process.

## **Why Each Wrong Option is Incorrect**
* **Option A:** is not typically associated with triggering malignant hyperthermia. It is a non-volatile anesthetic agent.
* **Option B:** is also not commonly linked with MH. It belongs to a different class of anesthetics.
* **Option C:** is not a trigger for malignant hyperthermia; it is actually used in the treatment of MH.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that malignant hyperthermia can be effectively treated with **dantrolene**, a specific antidote that inhibits calcium release from the sarcoplasmic reticulum. Early recognition and prompt treatment are crucial for patient survival.

## **Correct Answer Line**
**Correct Answer: D. **